Abstract:Background: Breast cancer is the most common cancer worldwide and the leading cause of female cancer-related deaths, highlighting the pressing need for novel therapeutic interventions. Treatment of triple negative breast cancer in particular remains a challenge due to disease aggressiveness and the lack of durable treatment options. We speculate that targeting of Lactate Dehydrogenase C (LDHC) could be a novel approach given its highly tumor specific expression and immunogenic properties. We recently demonstrated that LDHC acts as a key regulator of the DNA damage response and tumor mitotic fidelity. Moreover, silencing of LDHC significantly improved treatment response to DNA damage response related anti-cancer drugs, highlighting its therapeutic potential for cancer precision medicine. Methods: We characterized and evaluated several cell penetrating peptide-siRNA complexes for efficient silencing of LDHC in tumor cells using a 10R polyarginine peptide or bifunctional 10R-RGD, cRGD-10R or iRGD-10R peptides with tumor homing and penetrating abilities. Results: Peptide-siRNA complex formation and tumor cellular uptake was confirmed using gel retardation assays and fluorescent confocal imaging. Biophysiochemical characterization and transmission electron microscopy revealed the complexes to be uniform in size with a low polydispersity index and positive zeta potentials. LDHC silencing in breast cancer cells using the peptide complexes demonstrated a 30-53% reduction in LDHC expression, with the 10R-siRNA and cRGD-10R-siRNA complexes showing the highest silencing efficiency. In 3D breast cancer spheroids, transfection with the 10R-siRNA complex resulted in a 20% downregulation of LDHC expression. Further analysis of the bifunctional-siRNA complexes in 3D cultures is ongoing as well as cytotoxicity analyses on non-cancerous cell lines. Conclusions: Our findings demonstrate that peptide-mediated delivery of LDHC siRNA can reduce LDHC expression in 2D and 3D breast cancer cultures, suggesting that they could be used as a valuable approach for therapeutic intervention. Citation Format: Adviti Naik, Hanan Qasem, Julie Decock. Peptide-based siRNA delivery for tumor-specific targeting of lactate dehydrogenase C [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7255.

MUC1 aptamer-tethered H40-TEPA-PEG nanoconjugates for targeted siRNA-delivery and gene silencing in breast cancer cells

Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers

Effective Gene Silencing Mediated by Polypeptide Nanoparticles LAH4-L1-siMDR1 in Multi-Drug Resistant Human Breast Cancer.

A combinatorial delivery of survivin targeted siRNA using cancer selective nanoparticles for triple negative breast cancer therapy

Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model

Aptamer-guided DNA tetrahedron as a novel targeted drug delivery system for MUC1-expressing breast cancer cells in vitro

Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells

Poly(N-vinylpyrrolidone)- block-Poly(dimethylsiloxane)- block-Poly(N-vinylpyrrolidone) Triblock Copolymer Polymersomes for Delivery of PARP1 siRNA to Breast Cancers

Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors

Synergistic pH-responsive MUC-1 aptamer-conjugated Ag/MSN Janus nanoparticles for targeted chemotherapy, photothermal therapy, and gene therapy in breast cancer

Delivery of siRNAs Against Selective Ion Channels and Transporter Genes Using Hyaluronic Acid-coupled Carbonate Apatite Nanoparticles Synergistically Inhibits Growth and Survival of Breast Cancer Cells

Systemic siRNA Delivery with a Dual pH-Responsive and Tumor-targeted Nanovector for Inhibiting Tumor Growth and Spontaneous Metastasis in Orthotopic Murine Model of Breast Carcinoma

In Vitro Studies of Phospholipid-Modified PAMAM-siMDR1 Complexes for the Reversal of Multidrug Resistance in Human Breast Cancer Cells.

Multifunctional Nanoparticles Loaded with Vascular Endothelial Growth Factor Inhibitors and MED1 siRNA to Inhibit Breast Cancer Progression by Targeting Tumor-Associated Macrophages and Breast Cancer Cells

The Ph-Triggered Triblock Nanocarrier Enabled Highly Efficient Sirna Delivery for Cancer Therapy

Cationic Carbosilane Dendrimers for Apmnkq2 Aptamer Transfection in Breast Cancer: An Alternative to Traditional Transfectants.

Hyaluronidase-triggered Anticancer Drug and Sirna Delivery from Cascaded Targeting Nanoparticles for Drug-Resistant Breast Cancer Therapy

PD‐L1 Antibody‐Conjugated PAMAM Dendrimer Nanosystem for Simultaneously Inhibiting Glycolysis and Promoting Immune Response in Fighting Breast Cancer

Combination Antitumor Immunotherapy with VEGF and PIGF Sirna Via Systemic Delivery of Multi-Functionalized Nanoparticles to Tumor-Associated Macrophages and Breast Cancer Cells

Polyvalent Mesoporous Silica Nanoparticle-Aptamer Bioconjugates Target Breast Cancer Cells

Abstract 7255: Peptide-based siRNA delivery for tumor-specific targeting of lactate dehydrogenase C